UBS O'Connor’s Janux Therapeutics JANX Stock Holding History

UBS O'Connor’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,040	Closed	-$406K	–	425
2025 Q1	$406K	Buy	+15,040	New	+$567K	0.01%	228

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS O'Connor's JANX Position: Q2 2025 in Review

UBS O'Connor sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 15,040 shares — an estimated $406K sold.

UBS O'Connor first reported a position in JANX in Q1 2025 and held it in 1 quarter. The position peaked at $406K in Q1 2025. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

UBS O'Connor reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
UBS O'Connor sold 15,040 Janux Therapeutics shares in Q2 2025, an estimated $406K.
UBS O'Connor first reported a position in Janux Therapeutics in Q1 2025 and held it in 1 quarter.
UBS O'Connor's Janux Therapeutics position peaked at $406K in Q1 2025.
174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.